你买的不是工时。你买的是金字塔结构，这个结构决定了在确认参与率或归因结果前，有多少风险收入份额会被锁定。 数字健康公司面临的问题版本并不通用。结果风险的承诺速度快于公司判断自身能否承担的速度——12个月测量窗口对11个月销售周期——因此忽略风险收入份额的答案必然出错。分析必须从参与率和毛利率而非收入入手。
你买的不是工时。你买的是金字塔结构，这个结构决定了在确认参与率或归因结果前，有多少风险收入份额会被锁定。 数字健康公司面临的问题版本并不通用。结果风险的承诺速度快于公司判断自身能否承担的速度——12个月测量窗口对11个月销售周期——因此忽略风险收入份额的答案必然出错。分析必须从参与率和毛利率而非收入入手。
费用以单个项目总额形式出现，因为底层是金字塔结构：出售项目的合伙人出席指导会议，经理日常跟踪PMPM和结果，两到五名初级人员拉取 enrollment 和 churn 数据。客户支付由该比例决定的混合费率，而非pitch时见面人的资历，因此成本锁定在需要跨340,000名已注册成员归因结果的工作流数量上。
金字塔解释了以下模式：第二周后实际执行的人很少是出售项目的人，费用随销售周期长度而非证明毛利率的难度增长，缩小问题比降低费率节省更多，因为去掉一个归因结果工作流可削减四分之一团队。
更大成本在公司内部。项目反复占用财务负责人跟踪风险份额、运营负责人监控参与率、执行发起人审阅草案的时间，同时11个月销售周期仍在继续；这种内部负荷通常等于必须在12个月测量窗口关闭前完成的项目外部费用。
因此相关比较不是费用对费用，而是费用对它所支持的决策。旨在保护$62M ARR上风险收入份额的项目，与仅仅增加一个流失风险已在当前参与数据中可见的logo的项目不同，而后一种情况可以用内部资源完成同样输入，无需完整金字塔。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 提案中在任何关于待归因结果的单句定义达成前，就已呈现风险份额或PMPM预测。
✓ 财务或运营负责人每周已在参与率和logo流失数据拉取上花费多天，却无人将该时间计入项目预算。
✓ 提案仅说明总费用，未显示将有多少初级人员分配到结果跟踪，或该分配如何随工作流数量扩展。
通常会让情况更糟的做法。 只谈判混合费率而非归因结果工作流数量，后者仅削减一小部分费用，而费用大小由金字塔比例决定。
It is for you if you run or finance a digital health company and the proposal quotes a total and will not break out the team composition. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Corporate Strategy & Transformation, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
部分是品牌，部分是金字塔，但主要是风险转移。董事会从知名公司买来建议，若出错就有可辩护立场，而这种可辩护性是真实产品，有真实价格。如果无人需要保护——业主自行决定资本——你支付的是永远不会索赔的保险。
更便宜，是；等价，有时是。每天£1,000的有经验独立顾问常比三倍混合成本的初级团队给出更好判断，因为你缺的是判断。他们无法提供的是吞吐量——一人无法三周内访谈四十人。匹配你的约束是思考还是人手。
同类比较：软件取代分析，而非交付、关系或问责。公平比较是订阅对项目诊断阶段——通常£75k–£250k——而非整个项目。当诊断确实是你唯一需要的，差距很大。当不是，订阅无法弥合。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית